Fight for CME

It's unclear how or when the pharmaceutical industry became the new whipping boy for the press and Congress alike. Fair or unfair, this is the new reality, and since CME is largely funded by industry, we can expect the scrutiny to continue — even to intensify. Many of us are torn about how we should respond to the increasing criticism. Say too much, and we fear having the Congressional microscope turned on our own organizations. Say too little, and we fail to defend practices that improve

Register to view the full article

Register for and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.